Evidence map›Paper›PMID 32843180›Full record

Observational studyRespiratory medicine

Impact of SARS-CoV-2 infection in patients with cystic fibrosis in Spain: Incidence and results of the national CF-COVID19-Spain survey.

Pedro Mondejar-Lopez, Esther Quintana-Gallego, Rosa M Giron-Moreno, Isidoro Cortell-Aznar, Marta Ruiz de Valbuena-Maiz, Layla Diab-Caceres, Concepcion Prados-Sanchez, Antonio Alvarez-Fernandez, Patricia W Garcia-Marcos, Carlos Peñalver-Mellado and 11 more

Open access · greenAbstract readObservational Study
In one paragraph

Observational study in Respiratory medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 1 pooled it
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.

  1. Pooled it
  2. Genetic and chemical correction of cystic fibrosis reduces airway susceptibility to SARS-CoV-2.American journal of physiology. Lung cellular and molecular physiology · 2026
    Article
  3. Article
  4. Distinct Responses of Cystic Fibrosis Epithelial Cells to SARS-CoV-2 and Influenza A Virus.American journal of respiratory cell and molecular biology · 2025
    Article
  5. Article
  6. Review
  7. Review
  8. Mechanisms by which the cystic fibrosis transmembrane conductance regulator may influence SARS-CoV-2 infection and COVID-19 disease severity.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2023
    Article
  9. Article
  10. Article
  11. COVID-19 in a Cystic Fibrosis Patient.Oman medical journal · 2023
    Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. The clinical impact of the Covid-19 pandemic first wave on patients with cystic fibrosis in New York.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2022
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 15 institutions in 1 country.

Pedro Mondejar-LopezPediatric Pulmonology and Cystic Fibrosis Unit, Hospital Clinico Universitario Virgen de la Arrixaca, Murcia, Spain; Department of Surgery, Paediatrics, Obstetrics and Genecology, Universidad de Murcia, Spain. Electronic address: pedroe.mondejar@carm.es.
Esther Quintana-GallegoCystic Fibrosis Unit, Medical-Surgical Unit for Respiratory Diseases, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen Del Rocío, Sevilla, Spain; Centre for Biomedical Research Network of Respiratory Diseases (CIBERES), Instituto de Salud Carlos III, Madrid, Spain.
Rosa M Giron-MorenoCystic Fibrosis and Bronchiectasis Unit, Instituto de Investigacion, Hospital Universitario de la Princesa, Madrid, Spain.
Isidoro Cortell-AznarPediatric Pulmonology and Allergy Unit, Cystic Fibrosis Unit, Hospital Universitari i Politecnic La Fe, Valencia, Spain.
Marta Ruiz de Valbuena-MaizPediatric Pulmonology and Cystic Fibrosis Unit, Hospital Universitario La Paz, Madrid, Spain.
Layla Diab-CaceresAdult Cystic Fibrosis Unit, Pulmonology Service, Hospital Universitario 12 de Octubre, Madrid, Spain.
Concepcion Prados-SanchezPulmonology Service, Cystic Fibrosis and Bronchiectasis Unit, Hospital Universitario La Paz, Madrid, Spain.
Antonio Alvarez-FernandezAdult Cystic Fibrosis Unit, Pulmonology Service, Hospital Vall D'Hebron, Barcelona, Spain; Vall D'Hebron Institut de Recerca, Barcelona, Spain.
Patricia W Garcia-MarcosPediatric Pulmonology and Cystic Fibrosis Unit, Hospital Clinico Universitario Virgen de la Arrixaca, Murcia, Spain.
Carlos Peñalver-MelladoPulmonology Service. Hospital Clinico Universitario Virgen de La Arrixaca, Murcia, Spain.
M Dolores Pastor-ViveroOsakidetza. Organización Sanitaria Integrada Ezkerraldea-Enkarterri-Cruces, Hospital Universitario Cruces, Paediatrics, Cystic Fibrosis Unit, Bizkaia, Spain.
Casilda OlveiraCystic Fibrosis and Bronchiectasis Unit, Pulmonology Service, Hospital Regional Universitario, Malaga, Spain; Biomedical Research Institute of Malaga (IBIMA), Universidad de Malaga, Spain.
Alejandro Lopez-NeyraCystic Fibrosis Unit, Pediatrics Service, Hospital Universitario Ramón y Cajal, Madrid, Spain.
Silvia Castillo-CorullonPediatric Pulmonology and Cystic Fibrosis Unit, Hospital Clínico Universitario, Valencia, Spain.
Samara Palma-MillaEndocrinology and Nutrition Service, Cystic Fibrosis Unit, Hospital Universitario La Paz, Madrid, Spain.
Estela Perez-RuizCystic Fibrosis and Bronchiectasis Unit, Pulmonology Service, Hospital Regional Universitario, Malaga, Spain; Pediatric Pulmonology and Cystic Fibrosis Unit, UGC de Pediatría, Hospital Regional Universitario, Málaga, Spain.
Amparo Sole-JoverLung Transplantation and Cystic Fibrosis Unit, Hospital Universitario La Fe, Universidad de Valencia, Valencia, Spain.
M Isabel BarrioPediatric Pulmonology and Cystic Fibrosis Unit, Hospital Universitario La Paz, Madrid, Spain.
Manuel Sanchez-SolisPediatric Pulmonology and Cystic Fibrosis Unit, Hospital Clinico Universitario Virgen de la Arrixaca, Murcia, Spain; Department of Surgery, Paediatrics, Obstetrics and Genecology, Universidad de Murcia, Spain; Biomedical Research Institute of Murcia (IMIB), Murcia, Spain.
Óscar Asensio de la CruzCystic Fibrosis Unit, Pediatric Pulmonology and Allergy Unit, Hospital Universitari Parc Tauli, Sabadell, Barcelona, Spain; Faculty of Medicine, Universidad Autonoma de Barcelona, Spain.
CF-COVID19-Spain Registry Group
Hospital Universitario La Paz · ESHospital Universitario Virgen de la Arrixaca · ESHospital Clínico Universitario de Valencia · ESDeleted InstitutionHospital Regional Universitario de Málaga · ESHospital Universitario de La Princesa · ESHospital Universitari i Politècnic La Fe · ESHospital Universitario 12 De Octubre · ESHospital Universitario Ramón y Cajal · ESInstituto de Salud Carlos III · ESInstituto Murciano de Investigación Biosanitaria · ESOsakidetza · ESUniversidad de Málaga · ESUniversitat de València · ESVall d'Hebron Hospital Universitari · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGiven the high incidence of confirmed infection by SARS-CoV-2 and mortality by COVID-19 in the Spanish population, its impact was analysed among persons with Cystic Fibrosis (CF) as a group at risk of a worse evolution. The possible causes of the incidence observed in them are explained and how CF Units have faced this health challenge is detailed.

methodsRetrospective descriptive observational study, for which a Spanish CF Patients with Confirmed COVID-19 Registry is created, requesting information on number of people affected between 8 March-16 May 2020 and their clinical-demographic characteristics from the CF Units participating in the European Cystic Fibrosis Society Patient Registry (ECFSPR). The accumulated incidence is calculated, compared with that of the general population. Additionally, a survey (CF-COVID19-Spain) is carried out on prevention of SARS-CoV-2 infection, workings of CF Units and possible reasons for the incidence observed.

resultsCOVID-19 was diagnosed in eight CF patients, one of whom had received a lung transplant. The accumulated incidence was 32/10000 in CF patients and 49/10000 in the general population. General death rate was 5.85/10000 while no CF patients included in the ECFSPR died. The characteristics of those affected and the results of the survey are described.

conclusionsDespite being considered a disease at high risk of severe COVID-19, the low incidence and mortality in CF patients in Spain contrasts with the figures for the general population. The possible factors that would explain such findings are discussed, with the help of the results of the CF-COVID19-Spain survey.

Indexed as

Coronavirus InfectionsPandemicsPneumonia, ViralAdultBetacoronavirusClinical Laboratory TechniquesCOVID-19COVID-19 TestingCystic FibrosisFemaleHumansIncidenceMaleMortalityRegistriesRetrospective StudiesCoronavirusCOVID-19Cystic fibrosisSARS-CoV-2

Identifiers

PMID32843180
PMCPMC7831988
OpenAlexW3035115002

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.